Cerevel Therapeutics
(NASDAQ) CERE
This security has been delisted. This page is retained for historical reference.
CERE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowCERE Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-72%
Return on Capital
-39%
Return on Assets
-35%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$5.63M
Operating Income
$447.26M
EBITDA
$416.14M
Operating Cash Flow
$342.30M
Capital Expenditure
$3.81M
Free Cash Flow
$346.11M
Cash & ST Invst.
$990.97M
Total Debt
$480.78M
Cerevel Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$1.54M
-16.7%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
355
N/A
Net Income
$131.91M
-26.5%
EBITDA
$139.38M
-41.9%
Quarterly Fundamentals
Net Cash
$477.99M
+3.8%
Accounts Receivable
$4.96M
+55.0%
Inventory
$0.00
+100.0%
Long Term Debt
$364.79M
-0.4%
Short Term Debt
$3.52M
+16.1%
Return on Assets
-34.81%
N/A
Return on Invested Capital
-38.85%
N/A
Free Cash Flow
$119.94M
-25.9%
Operating Cash Flow
$119.67M
-26.1%